Patient Centricity

The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality

Patient centricity: A defining imperative in healthcare As patient expectations evolve and regulatory bodies demand greater transparency, the pharmaceutical industry is undergoing a profound transformation in terms of patient centricity. Our latest white paper, “The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality,” explores how patient centricity has shifted from…...
Read More

Top Stories

NASSCOM GCC Summit 2025

What’s Next for Global Capability Centers )?

The theme for this year’s NASSCOM GCC Summit, “The Next GCC...
MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook

At the MAPS Americas 2025 conference in New Orleans, one of...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...
man-accessing-data

New Open Data Sharing Policies: WHO and NIH Take Big Steps to Improve Public Health

Making research and data reproducible is vital to improving public health and reinstating trust in...
a-man-questioning-medical-device-regulatory-options

Which Regulatory Requirements Are Applicable to “Legacy” Devices?

Understanding the requirements for your medical device is vital in today’s market. But are these...
image manipulation

Avoid the Pitfall of Image Manipulation

8 major publishers unite to solve the image manipulation problem in research publications. Here's a...

MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)

An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Medical Affairs - 2025

Vision 2025: Decoding the Medical Affairs Landscape

Medical Affairs is a critical strategic pillars of pharma. Read how Medical Affairs will evolve...

Learn more ABOUT our company.